SCHEMBL7429589

SCHEMBL7429589

NC(=S)c1ccc(I)cc1

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
TPMT P51580 1/20 0.46
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44
SLC22A2 O15244 1/20 0.42
SLC22A1 O15245 1/20 0.42
SLC22A3 O75751 1/20 0.42
IDO1 P14902 1/20 0.41
GSK3B P49841 1/20 0.39
ASH1L Q9NR48 1/20 0.38
PRKCI P41743 1/20 0.36
PHGDH O43175 1/20 0.36
MAPT P10636 1/20 0.36
PKM P14618 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2206586 0.85 HTT (0.62) HTTSMN1; SMN2ASH1LPRKCIMAPT
SCHEMBL469734 0.74 LMNA (0.55) HTTSMN1; SMN2CA1CA2MAPT
SCHEMBL6346842 0.74 TPMT (0.55) TPMTCA1CA2SLC22A2SLC22A1
SCHEMBL14018619 0.74 HTT (0.58) HTTSMN1; SMN2ASH1LMAPTPKM
SCHEMBL5068709 0.72 TPMT (0.46) TPMTCA1CA2SLC22A2SLC22A1
SCHEMBL999667 0.72 HTT (0.50) HTTSMN1; SMN2CA1CA2SLC22A2
SCHEMBL354613 0.72 HTT (0.56) HTTSMN1; SMN2CA1CA2SLC22A2
SCHEMBL10503095 0.72 HTT (0.50) HTTSMN1; SMN2IDO1ASH1LPRKCI
SCHEMBL22130014 0.72 HTT (0.50) HTTSMN1; SMN2CA1CA2SLC22A2
SCHEMBL7426560 0.72 LMNA (0.59) PKMHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115219644-A By means of H 2 Activity evaluation device and method for S-prepared aryl thioamide catalyst 福州大学 2022-10-21 CN disclosed
US-10414759-B2 Phenylthiazoles and uses thereof PURDUE RESEARCH FOUNDATION (US) 2019-09-17 US disclosed
US-9801861-B2 Antimicrobial substituted thiazoles and methods of use PURDUE RESEARCH FOUNDATION (US) 2017-10-31 US disclosed
US-9801861-B2 Antimicrobial substituted thiazoles and methods of use PURDUE RESEARCH FOUNDATION (US) 2017-10-31 US disclosed
US-20160243088-A1 ANTIMICROBIAL SUBSTITUTED THIAZOLES AND METHODS OF USE PURDUE RESEARCH FOUNDATION (US) 2016-08-25 US disclosed
US-20160243088-A1 ANTIMICROBIAL SUBSTITUTED THIAZOLES AND METHODS OF USE PURDUE RESEARCH FOUNDATION (US) 2016-08-25 US disclosed
US-9353072-B2 Antimicrobial substituted thiazoles and methods of use PURDUE RESEARCH FOUNDATION (US) 2016-05-31 US disclosed
US-9353072-B2 Antimicrobial substituted thiazoles and methods of use PURDUE RESEARCH FOUNDATION (US) 2016-05-31 US disclosed
US-20140121249-A1 ANTIMICROBIAL SUBSTITUTED THIAZOLES AND METHODS OF USE PURDUE RESEARCH FOUNDATION 2014-05-01 US disclosed
US-20140121249-A1 ANTIMICROBIAL SUBSTITUTED THIAZOLES AND METHODS OF USE PURDUE RESEARCH FOUNDATION 2014-05-01 US disclosed
CN-1220681-C Indole derivatives as XA factor inhibitors AVENTIS MEDICINES DEUTSCHLAND (DE) 2005-09-28 CN disclosed
US-6337344-B1 ANTICOAGULANTS AND ENZYME INHIBITORS FOR CARDIOVASCULAR DISORDERS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-01-08 US disclosed
CN-1283186-A Indole derivatives as XA factor inhibitors AWENTIS MEDICINES DEUTSCHLAND (DE) 2001-02-07 CN disclosed
EP-1042287-A1 INDOLE DERIVATIVES AS INHIBITORS OF FACTOR XA Aventis Pharma Deutschland GmbH (DE) 2000-10-11 EP disclosed
WO-1999033800-A1 INDOLE DERIVATIVES AS INHIBITORS OR FACTOR XA AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 1999-07-08 WO disclosed
US-5182402-A 2-Phenylthiazolecarboxylic Acids and Esters IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1993-01-26 US disclosed
US-5084083-A Phenylthiazolecarboxylic acid derivative herbicides IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1992-01-28 US disclosed
CN-1042907-A Herbicidal composition ICI PLC (GB) 1990-06-13 CN disclosed
EP-0368592-A1 Herbicidal compositions IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1990-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10414759-B2 Phenylthiazoles and uses thereof TPMT, TST, CLPP HTT 3052/4885SMN1; SMN2 3041/4885TPMT 1/4885
US-20140121249-A1 ANTIMICROBIAL SUBSTITUTED THIAZOLES AND METHODS OF USE CLPP, ELANE, NOD2 HTT 2691/4885SMN1; SMN2 3558/4885TPMT 395/4885
US-20160243088-A1 ANTIMICROBIAL SUBSTITUTED THIAZOLES AND METHODS OF USE CLPP, ELANE, NOD2 HTT 2691/4885SMN1; SMN2 3558/4885TPMT 395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.